HONG KONG, Jan. 9, 2023 /PRNewswire/ -- Luye Pharma Group today announced the launch of the Named Patient Program (NPP) in Hong Kong, China, providing eligible local patients immediate access to the innovative anti-cancer therapy Lurbinectedin. Luye Pharma has signed an agreement with Abacus Medicine Pharma Services (AMPS), an international...